TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alpha Tau Medical Ltd ( (DRTS) ) has provided an update.
On December 4, 2025, Alpha Tau Medical Ltd. announced the acceptance of two abstracts related to its Alpha DaRT technology for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium. These abstracts, focusing on pancreatic cancer, highlight the company’s ongoing clinical trials, including a multi-center study in the U.S. that began in September 2025. This development underscores Alpha Tau’s commitment to addressing high unmet needs in cancer treatment, particularly for pancreatic cancer patients who often face limited treatment options.
The most recent analyst rating on (DRTS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
Spark’s Take on DRTS Stock
According to Spark, TipRanks’ AI Analyst, DRTS is a Underperform.
Alpha Tau Medical Ltd is struggling with significant financial challenges, primarily due to a lack of revenue and ongoing cash burn. While technical indicators show a neutral trend, the valuation metrics reflect the company’s unprofitability. The absence of earnings call insights and corporate events limits additional context. Overall, the stock is risky with a low score of 38, suggesting caution for potential investors.
To see Spark’s full report on DRTS stock, click here.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company specializing in the research, development, and potential commercialization of Alpha DaRT, an innovative alpha-radiation cancer therapy designed for the treatment of solid tumors.
Average Trading Volume: 60,682
Technical Sentiment Signal: Buy
Current Market Cap: $327.8M
For detailed information about DRTS stock, go to TipRanks’ Stock Analysis page.